Osteoporosis Risk in Corticosteroid Therapy

Introduction to Osteoporosis Risk

The American College of Rheumatology recommends that adults who initiate or continue corticosteroid therapy for more than 3 months with ≥2.5 mg/day should undergo clinical fracture risk assessment, bone density measurement, and FRAX calculation, as the maximum bone loss occurs within the first 3-6 months of therapy 1, 2
The fracture risk peaks after 12 months of corticosteroid therapy, with both high daily doses (≥30 mg/day) and high cumulative doses (≥5 g/year) significantly increasing the risk of fragility fractures 1, 3

Doses ≥2.5 mg/day of prednisone equivalent increase the fracture risk at the spine and hip, according to the American College of Rheumatology 1, 3
Doses <2.5 mg/day already increase the risk of vertebral fractures, emphasizing the need for early assessment and intervention 1, 3
Very high doses (≥30 mg/day initially or cumulative dose >5 g/year) lead to a significantly increased fracture risk, which may be underestimated by standard risk calculators 1, 3

For adults with moderate, high, or very high fracture risk, pharmacological treatment is strongly recommended, including oral or intravenous bisphosphonates, denosumab, or parathyroid hormone analogs as first-line therapy, as per the American College of Rheumatology guidelines 1, 2
Anabolic substances are conditionally recommended as initial therapy for high and very high fracture risk patients, with the choice of treatment depending on shared decision-making 1

The risk of fracture should not be underestimated, even at low doses, as doses <2.5 mg/day can increase the risk of vertebral fractures 1, 3
Prevention should be started early, as bone loss is most significant in the first 3-6 months of therapy, and assessment and treatment should be initiated as soon as possible after starting therapy 1, 2
Special populations, such as those on very high doses (≥30 mg/day), should be carefully evaluated, as standard risk calculators may underestimate their actual fracture risk 1, 3